Vitamin D3 and brain wave patterns in men with Parkinson's disease and low vitamin D

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-arm, pretest-posttest trial enrolling 15 men with Parkinson's disease, confirmed low serum 25(OH)D, and Hoehn and Yahr stage up to 3. Participants will take oral vitamin D3 50,000 IU once weekly for 8 weeks and return for repeat serum 25(OH)D measurement and quantitative EEG. qEEG recordings will be processed with FFT to derive absolute and relative power, peak and median power frequency, and spectral edge frequency across delta, theta, alpha and beta bands. Within-subject changes will be analyzed using paired t-tests or Wilcoxon signed-rank tests after normality testing in SPSS.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male Patients with PD up to stage 3 according to Hoehn and Yahr (H-Y) scale
* Age: 51years to70 years
* BMI: 18.5-24.9 kg/m2
* Hypovitaminosis D (Serum 25(OH)D level \<30 ng/ml)
* Patients on Levodopa therapy

Exclusion Criteria:

* Already taking vitamin D3 supplements
* Current use of medication/substances known to affect neuronal excitability or EEG patterns, such as - sedatives, antidepressant, antipsychotics, alcohol.
* Patients who are currently suffering from following diseases

  * Neurological disorders (Migraine, epilepsy)
  * Cardiovascular disorders (Myocardial infarction, hypertension, cardiac arrhythmia, heart failure)
  * Respiratory disorders (Bronchial asthma, COPD)
  * Psychiatric illness (e.g., schizophrenia, major depression, bipolar disorder, severe dementia)
* With biochemical evidence of-

  * Hypercalcemia
  * Renal insufficiency
  * Liver diseases
  * Endocrine disorders (uncontrolled diabetes mellitus, Hypothyroidism, Hyperthyroidism)
* Active smoker

Where it's running

• Bangladesh medical university
  Dhaka, Shahbag, Bangladesh Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• UX-DA003 injections for Parkinson's disease

  This early-phase trial tests whether injecting UX-DA003 is safe and may help motor symptoms in people with Parkinson's whose response to standard treatments has declined.

  Recruiting Early Phase 1 The First Affiliated Hospital of Anhui Medical University · Hefei, Anhui · NCT07911670

• Strength and dual-task training to help people with Parkinson’s improve strength and function

  This trial tests three levels of physiotherapy, including progressive resistance training with and without cognitive dual-task and instability components, to see if they improve muscle strength, body composition, and physical function in adults with Parkinson’s or related syndromes.

  Recruiting University of Valencia · Valencia, Valencia · NCT07907302

• Spinal Mobility, Rigidity, and Kinesiophobia in Parkinson's Disease with and without TMD

  This study tests whether people with Parkinson's disease who have Temporomandibular Disorders differ in spinal mobility, axial rigidity, and kinesiophobia from those without TMD.

  Recruiting Mustafa Kemal University · Hatay · NCT07850674

• A 12-Week Trial of Flexilev with the OraFID Device and App for Parkinson's

  This study tests whether taking small, precise doses of Flexilev with the OraFID dosing device and Levilog app is acceptable and helps people with Parkinson's manage their medicine.

  Recruiting at 2 sites Phase 4 Navamedic AB · Stockholm, Stockholm County and 4 other locations · NCT07839793

• Integrated Motor-Cognitive Training in Parkinson's Disease

  This study tests a combined motor and cognitive rehabilitation program to see if people with Parkinson’s disease can stick with it and show early signs of benefit.

  Recruiting University Hospital of Ferrara · Ferrara, FE · NCT07833748

• VIM0423 for Parkinson's Tremor in Adults Not Fully Controlled by Dopaminergic Therapy

  A Vima Therapeutics study tests whether the oral drug VIM0423 can reduce tremor in adults with Parkinson’s disease who still have tremor despite dopaminergic treatment.

  Recruiting at 4 sites Phase 2 Vima Therapeutics · Scottsdale, Arizona and 29 other locations · NCT07804615

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.